Individual Factors of CBT Underlying Success
Launched by UNIVERSITY OF WASHINGTON · Nov 5, 2024
Trial Information
Current as of August 29, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Individual Factors of CBT Underlying Success," is focused on understanding why some people with social anxiety disorder (SAD) or body dysmorphic disorder (BDD) respond well to cognitive behavioral therapy (CBT), while others do not. Researchers will gather various types of information, including brain scans, cognitive tests, and personal feedback, to find clues about what makes therapy effective for some individuals and less so for others.
To participate, you need to be between the ages of 18 and 45 and have a diagnosis of either SAD or BDD. If you do not have any psychiatric disorders and have low levels of anxiety and depression, you could also be part of the control group. Participants will be asked to provide their consent and will undergo assessments to ensure they meet the study criteria. If you join the trial, you'll be contributing to important research that could help improve treatment for people with these conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Clinical sample (N=110):
- • 1. Men and women, age 18-45
- • 2. Treatment-seeking individuals who meet criteria for a primary DSM-5 diagnosis of primary social anxiety disorder (SAD) or body dysmorphic disorder (BDD) based on the SCID-5-RV
- • 3. Fluent in English and willing to provide informed consent.
- Control sample (N=50):
- • 1. Men and women, age 18-45
- • 2. No current or lifetime history of psychiatric disorders, as assessed using the SCID-5-RV
- • 3. Meet criteria for low levels of anxiety (GAD-7 score of \<8) and depression (PHQ-9 score \<10)
- • 4. Fluent in English and willing to provide informed consent
- Exclusion Criteria:
- All groups:
- • 1. Score \< 80 based on WRAT5 Word Reading Subtest
- • 2. fMRI contraindications (e.g., electronic medical devices such as pacemakers, implanted defibrillators, etc.; metal implants not approved for MRI; pregnancy; claustrophobia)
- • 2. Active suicidal or homicidal ideation, or any features requiring a higher level of care 3. Lifetime history of manic or hypomanic episode, psychotic symptoms, traumatic brain injury, neurological disorder, pervasive developmental disorder, or attention deficit-hyperactivity disorder; active alcohol or substance use disorder in the past 6 months 4. Current use of psychotropic medications, except antidepressants taken at a stable dose for 3 months prior to study baseline 5. Previous CBT non-responder or current CBT
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seattle, Washington, United States
Patients applied
Trial Officials
Angela Fang, PhD
Principal Investigator
University of Washington
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported